0000000000392674

AUTHOR

L. Crosta

showing 7 related works from this author

Erythromycin reverses the daunomycin resistance of MEL-DRTL cells

1990

PharmacologyChemistrymedicineErythromycinPharmacologymedicine.drugPharmacological Research
researchProduct

Does catalase play a role in Adriamycin induced cardiotoxicity?

1980

Summary Adriamycin causes an increase of lipid peroxidation in mouse cardiac homogenates that is dependent on the concentration of the antiblastic. The same phenomenon is not observed in the hearts of mice treated with an elevated dose of Adriamycin in which, conversely, an increase of the antioxidizing enzyme catalase was noticed. The significance of these findings is discussed with relationship to the hypothesis of an enhanced free radicals formation at the basis of Adriamycin induced cardiotoxicity.

chemistry.chemical_classificationPharmacologyCardiotoxicityLipid PeroxidesbiologyFree RadicalsHeart DiseasesMyocardiumPharmacologyNADCatalaseMalonatescarbohydrates (lipids)Lipid peroxidationchemistry.chemical_compoundMiceEnzymechemistryCatalaseDoxorubicinMalondialdehydepolycyclic compoundsbiology.proteinAnimalsFemalePharmacological Research Communications
researchProduct

Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells

2008

Resistance to imatinib mesylate is an emergent problem in the treatment of Bcr-Abl expressing myelogenous leukemias and additional therapeutic strategies are required. We observed that galangin, a non-toxic, naturally occurring flavonoid was effective as anti-proliferative, and apoptotic agent in Bcr-Abl expressing K562 and KCL22 cells and in imatinib mesylate resistant K562-R and KCL22-R cells. Galangin induced an arrest of cells in G0–G1phase of cell cycle and a decrease in pRb, cdk4, cdk1, cycline B levels; moreover, it was able to induce a monocytic differentiation of leukemic Bcr-Abl+ cells. Of note, galangin caused a decrease in Bcl-2 levels and markedly increased the apoptotic activi…

Cancer ResearchSettore MED/17 - Malattie InfettiveSettore MED/06 - Oncologia MedicaApoptosisPharmacologyResting Phase Cell CyclePiperazineschemistry.chemical_compoundCell Line TumorLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCytotoxic T cellChrysinneoplasmsFlavonoidsLeukemiaG1 PhaseApoptosiCell DifferentiationImatinibmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGalanginLeukemiaPyrimidinesImatinib mesylateOncologychemistryDrug Resistance NeoplasmImatinibBenzamidesSettore BIO/14 - FarmacologiaImatinib MesylateK562 CellsFisetinBcr-AblK562 cellsmedicine.drugCancer Letters
researchProduct

Influence of Mitoxantrone on the Syntheses of Dna and Proteins of Mouse Tissues

1991

In view of the structural similarity of mitoxantrone to anthracyclines and its ability to intercalate into DNA, we studied its influence on the synthetic processes of DNA and proteins in CD-1 mice tissues. By studying at the DNA level the impairment of 2H-thymidine incorporation and its return to normal, it was found that bone marrow and spleen showed similar behavior, i.e., a rapid return to normal, which occurred before bone marrow cell number and spleen weight returned to basal values. At the cardiac level, the incorporation values of precursors into DNA, reduced by treatment with mitoxantrone, came back very slowly to the control ones. Hepatic DNA showed a lower sensitivity to mitoxant…

Cancer ResearchStructural similarityMuscle ProteinsSpleen030218 nuclear medicine & medical imagingMice03 medical and health sciencesBasal (phylogenetics)chemistry.chemical_compound0302 clinical medicineBone MarrowmedicineAnimalsDoxorubicinMitoxantroneCumulative doseChemistryMyocardiumHeartDNAGeneral MedicineMolecular biologymedicine.anatomical_structureLiverOncology030220 oncology & carcinogenesisBone marrowMitoxantroneSpleenDNAmedicine.drugTumori Journal
researchProduct

Isolated myocardiocytes and DNA synthesis: a possible experimental model to predict the in vivo cardiotoxicity

1989

PharmacologyCardiotoxicityHeart DiseasesDNA synthesisBiological modelingbusiness.industryExperimental modelMyocardiumDNAPharmacologyModels BiologicalRatsMiceDoxorubicinIn vivoToxicityAnimalsMedicineMitoxantronebusinessPharmacological Research
researchProduct

Growth hormone protects human lymphocytes from irradiation-induced cell death

2003

1. Undesired effects of cancer radiotherapy mainly affect the hematopoietic system. Growth hormone (GH) participates in both hematopoiesis and modulation of the immune response. We report both r-hGH cell death prevention and restoration of secretory capacities of irradiated human peripheral blood lymphocytes (PBL) in vitro. 2. r-hGH induced cell survival and increased proliferation of irradiated cells. Western blot analysis indicated that these effects of GH were paralleled by increased expression of the antiapoptotic protein Bcl-2. 3. r-hGH restored mitogen-stimulated release of IL-2 by PBL. Preincubation of irradiated lymphocytes with the growth hormone receptor (GHR) antagonists B2036 an…

Pharmacologymedicine.medical_specialtyProgrammed cell deathmedicine.diagnostic_testCellCancerGrowth hormone receptorBiologymedicine.diseaseHaematopoiesisEndocrinologymedicine.anatomical_structureImmune systemWestern blotApoptosisInternal medicinemedicineCancer researchhormones hormone substitutes and hormone antagonistsBritish Journal of Pharmacology
researchProduct

Cathepsin D, B and L circulating levels as prognostic markers of malignant progression

1996

Growing evidence indicates that lysosomal Cathepsins D (CD), B (CB) and L (CL) may promote carcinogenesis and tumor progression. Therefore, we evaluated their potential value as biochemical parameters of malignant progression in patients with benign diseases which may undergo malignant transformation, such as liver cirrhosis (LC) and chronic pancreatitis (CHP) as well as in hepatocellular carcinoma (HCC) and pancreatic cancer (DPC). CD, CB and CL serum levels were determined by immunoenzymatic assays in LC, CHP, HCC or DPC patients and correlated with a number of biochemical and clinical parameters of these diseases. CD serum levels were increased in LC, CHP and HCC, but not in the DPC grou…

AdultAged 80 and overMaleTumor progression.Carcinoma HepatocellularCirrhosiVHepatocellular carcinomaCathepsin LLiver NeoplasmsPancreatic cancerMiddle AgedPrognosisCathepsin DCathepsinsLCathepsin BPancreatic NeoplasmsCysteine EndopeptidasesChronic HepatiticEndopeptidasesBiomarkers TumorHumansFemaleAged
researchProduct